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Abstract 
Cell therapies, especially autologous therapies, pose significant challenges to researchers who wish to 
move from small, probably academic, methods of manufacture to full commercial scale. There is a 
dearth of reliable information about the costs of operation, and this makes it difficult to predict with 
confidence the investment needed to translate the innovations to the clinic, other than as small-scale, 
clinician-led prescriptions. Here, we provide an example of the results of a cost model that takes into 
account the fixed and variable costs of manufacture of one such therapy. We also highlight the different 
factors that influence the product final pricing strategy. Our findings illustrate the need for cooperative 
and collective action by the research community in pre-competitive research to generate the operational 
models that are much needed to increase confidence in process development for these advanced 
products. 
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In the past decade, there has been a rapid increase in the development of autologous cell 
therapies, with several investigational products demonstrating encouraging clinical outcomes, 
especially in immunotherapies. It has been recognized, for instance, that adoptive transfer of in 
vitro expanded virus-specific T cells can prevent and also effectively treat viral infectious 
complications in immunocompromised patients after solid organs (SOT) or hematopoietic 
stem-cell transplantation (HSCT) (1–4). Infectious complications that arise due to 
immunosuppression, that organ recipients need for the lifetime of the transplanted organ to 
prevent rejection, are mainly caused by the cytomegalovirus (CMV), BK virus, and the Epstein 
- Barr virus (EBV) (5). Although the adoption of universal antiviral prophylactic strategies has 
significantly reduced the incidence of CMV infection and disease, the development of drug-
resistant and late-onset CMV disease after discontinuation of these prophylactic antivirals is 
prone to high risk of  malignancy, graft loss and mortality (6), and associated with a significant 
rise in treatment costs (7). Additionally, other serious adverse events such as nephrotoxicity 
and neutropenia can also result from the administration of antiviral agents (8). Thus, adoptive 
immunotherapies associated with lower toxicities for the prevention and treatment of CMV 
infection and disease are highly needed and may also produce overall cost savings in post-
transplant patient care. Indeed, a recent study has suggested that even if the prevention 
capabilities of antiviral donor-derived cytotoxic T lymphocytes (CTL) in HSCT, which cost 
$10,000 to manufacture, would only be 50% effective at avoiding the need for antiviral 
treatment, it is still considered the less expensive option compared to the cost of antiviral 
treatment and associated hospital care of more than $50,000 per patient (9). Researchers 
working in this field anticipate that such therapies could replace conventional treatments, 
possibly allowing this novel therapeutic category to be accepted as standard practice (10). 
However, if these products are to find their way into routine clinical practice, obvious hurdles 
associated with their lengthy development timelines, pricing, reimbursement and 
commercialization need to be addressed and overcome. We sought to identify and describe 
some of these challenges from the perspective of academic institutions developing these 
advanced therapies. We are also providing a relevant case study to illustrate a detailed measure 
of manufacturing costs of a CMV-specific T cell immunotherapy. 
Developing a tailored business model for cell therapies 
Autologous cell therapies are patient-specific products that require a considerable degree of 
flexibility in their manufacturing process, while following the principles of Good 
Manufacturing Practice (GMP), as mandated by regulations (11) and guidelines (12). Any 
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business models developed for the commercialization of autologous therapies therefore differ 
substantially from those used for small molecule drugs or other biologics. In order to compete 
with small molecule pharmaceuticals on the market, which are normally cheaper to 
manufacture, autologous cell therapies need to demonstrate superior safety and at least 
equivalent, if not better efficacy as compared to the available standard of care, or should be 
applicable in diseases with no available therapeutic treatments. Interestingly, setting a market 
price for autologous cellular therapies is very ambitious where complex supply logistics, the 
need to scale out, rather than scale up, production and the lack of transparency of the production 
costs, due to the large variety of manufacturing operations, are characteristic of the sector. A 
significant cost contribution also arises from the fixed manufacturing overhead costs and these 
can be difficult to quantify without detailed studies. Therefore, new and tailored prospective 
economic models are required for autologous cell therapy products that focus rather on 
optimizing the operational efficiency while reducing risks associated with the manufacturing 
process (13, 14). By reducing the manufacturing costs of these products, which are typically 
driven by sophisticated manufacturing facilities, highly trained labor, expensive materials and 
high overheads for assurance of quality, the final price tag of autologous cell therapies can reach 
a more affordable level (15). 
 Several authors of this paper reported in 2013 a novel cost model (CTAT or Clean Technology 
Assessment Technique) that integrates manufacturing economics and optimization approaches 
to accurately assess the optimal cost of producing a clinical grade cell therapy product (13). 
The possible strength of this proposed model lies in the vigorous approach to splitting the 
interdependence between costs resulting from operating a GMP facility and those resulting from 
manufacturing a specific cellular product. Although annual direct and indirect operating costs 
represented in personnel, utilities, maintenance, quality management system, materials and 
supplies are already covered by the model, additional costs that can result from expanding the 
infrastructure and purchasing new equipment to accommodate increased demand for 
production, need to be included in a sequential application of the model. CTAT is also 
dependent upon local and regional cost variations for materials and services, limited to the 
manufacturing costs of the therapy, and does not account for costs of research and development 
(R&D). Nevertheless, the model may still help to provide a snapshot of the commercial viability 
of cell- and gene therapies by accurately estimating the cost of goods (CoG). Without any doubt, 
if such products are to be introduced into the pharmaceutical market, their price will be several-
fold higher than the CoG in order to cover R&D costs, expenses incurred in translational 
research and marketing, plus generating a profit, which is essential for the developer`s survival 
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and growth. In order to make the cost assumptions in such a tailored business model robust 
enough to support ongoing sustainability and to increase the applicability of its results, the key 
cost drivers in the manufacturing of cell therapy products should be examined and understood. 
Identifying the key cost drivers in manufacturing cell therapies 
 The relevant manufacturing costs of cellular products can be broken down into direct (variable) 
and indirect (fixed) costs. Material, personnel costs, and process validation costs are examples 
of direct costs that have a variable cost share, depending on the manufacturing volume. 
Preventive maintenance, amortization of facility and equipment capital purchases and 
environmental monitoring are examples of indirect costs which have a fixed cost share, 
independent of actual GMP facility utilization times for product manufacturing. For the total 
variable costs, the cost driver is the number of manufacturing runs carried out in the facility. 
For the total fixed costs, cost drivers are GMP facility size, personnel wages (including support 
services such as finance, marketing, maintenance and legal services) and the degree of 
optimization of the manufacturing process, including the failure and wastage rate of batch 
production. For most cellular therapies, the major cost driver for the unit fixed cost (the cost of 
a single therapeutic cellular product), is the duration of the manufacturing process. An increase 
in product manufacturing time results in a linear increase in fixed costs. For products that need 
only little manufacturing time, variable costs are the dominant cost share. Nevertheless, other 
aspects, such as costs for scale-up equipment, dedicated to only some of the manufactured 
products, can still contribute to a higher percentage of costs than the GMP manufacturing time.  
It is apparent that the scale of manufacturing is another important cost driver in the production 
process of cell therapies (14). Usually, calculating the production capacity of a manufacturing 
facility should be based on a supply and demand relationship. In most of the cost modeling 
efforts, capacity constraints are ignored and production costs are assumed to be linear, thereby 
limiting the degree to which costs are realistic. This is often done since accounting for 
production scale economy can significantly complicate the pricing process of a product.  Such 
activity does not come easily to those without prior experience of the process in question or 
without operational management experience. Since increasing production levels reduces the 
contribution of the fixed costs of operating GMP facilities to the manufacturing cost per unit, 
developers always aim to improve their scale-up capabilities. For instance, in a phase I or I/II 
clinical trial investigating an autologous therapeutic cellular product, more than two products 
could be manufactured per incubator given good physical separation and changeover 
procedures after product manufacturing cycles. If closed systems are used, such as the Octane 
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Cocoon (Octane Biotech Inc.) (16) or the G-Rex M (Wilson Wolf Manufacturing) (17) 
bioreactor platforms, only spatial limits and points in the process where manual handling 
imposes a bottleneck will constrain the number of products that could be manufactured in 
parallel. This relation between scaling up production and reduction of costs is further explained 
in a hypothetical break-even point analysis (Figure 1). To that end, the identification of the key 
economic drivers in manufacturing cell therapies and their inclusion in any attempt to reduce 
the associated manufacturing costs can help to contain escalating prices.  
Preparing for lengthy development timelines and stringent regulatory requirement  
Due to the media attention that new cell therapy products attract there is high public expectation 
for rapid availability of the therapies. In spite of that, developers who are keen on translating 
novel therapeutic strategies into the clinic need to be well equipped financially in order to 
succeed in their efforts. Some larger commercial developers do not have any expectation of 
substantial revenue derived from these novel products; they instead rely on less advanced 
products that have a less demanding regulatory pathway or that already have an established 
market share, in order for them to survive financially. However, this mixed-portfolio strategy 
may not be feasible for small startups and academic institutions that lack a back-catalogue of 
such products to secure a revenue stream. Even after securing the needed funding for the long 
development phase, maintaining the highly-specialized GMP production facilities is very costly 
and requires a substantial upfront investment and the willingness to support a high burn rate of 
maintenance costs. This may be responsible for the very low percentage of academic developers 
who expect their products to be implemented into regular clinical care (18). Instead, they turn 
to specific fast track regulatory pathways such as the ‘Hospital Exemption’ and ‘Specials’ 
routes in Europe (19) to treat patients earlier, and without having to go through the burdensome 
process of getting the cell product to commercial scale. Other small biotech companies rely on 
addressing unmet medical conditions and the possibility of obtaining an orphan drug 
designation for their products which can speed up the regulatory approval pathway (14) and 
generate adequate cash flow during the pre-market period. However, this does not necessarily 
guarantee commercial success (20). One must also note that most academic developers are 
using public funds in their translational process. Therefore, the development of a much-needed 
novel therapeutic will be funded by taxpayer money. If attempts are to be made to accelerate 
the translation of such products to market, it would be necessary to license them to industrial 
manufacturers at a reasonable price (15), on the basis that affordable pricing should be 
maintained when selling such products. 
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The regulatory approach for the clinical translation of any cell or gene therapy product is highly 
dependent on their intended clinical use, methods of manufacturing and the specific national 
regulations where they are being developed (21). Even though the regulatory framework for 
cell therapies in Europe may be perceived by some as rigid and exhaustive (22), the regulatory 
authorities recognize the importance of ensuring patient access to safe, effective medicines and 
are exerting tremendous efforts to address these concerns (23). This is evident in the 
introduction of the new EU clinical trials regulation which aims to harmonize the divergent 
regulatory requirements of the different member states in case of multistate clinical trials, 
among other aspects (24). Moreover, the European Commission has initiated a procedure for 
consultation on new guidelines on Good Manufacturing Practices, specific for advanced 
therapy medicinal products. Although these efforts have been positively perceived by the 
majority of the scientific community, they do not come without major challenges. For instance, 
the new EU clinical trials regulation  mandates a very strict timeline for the evaluation process 
of clinical trial applications, which may be  difficult to comply with for small academic groups 
developing advanced therapies (24). Also, some fear that the new GMP guideline may be 
intended to create double standards, depending on whether advanced therapies are 
manufactured by industry or by academic manufacturers (25). In either way, regulatory 
guidance should continue to evolve in order to prevent the growing use of unproven cell 
therapies that encourages medical tourism (26) and to shorten the development timelines of 
these therapies which, in turn, will lower their market prices. For this, academic institutions 
who are involved in the development of cell therapies should establish collaborations between 
their centers and engage in a responsible collective dialogue with the appropriate regulatory 
agencies to speed up their translational processes (21). 
Reaching a successful reimbursement rate   
Reimbursement of cell and gene therapies is currently one of the most debated topics in the 
adoption process of novel technologies into the medicinal products market. On one hand, if 
developers fail to reach a reimbursement rate that covers their incurred expenses, the product 
as well as the business structure behind it will never be able to survive in the open market. On 
the other hand, offering cell and gene therapies as highly overpriced products will not help them 
to achieve commercial stability through adequate market penetration (27). Immunotherapies 
such as antigen-specific T-cells may actually offer the patients the best chance for less toxicity, 
higher potency and improved quality of life in comparison to the available antiviral drug 
regimen (28). However, under the current methods of insurance reimbursement, such products, 
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yet with limited well-defined real-world benefits, may not be seen as addressing an unmet 
clinical need, or their potential benefits may not outweigh their costs. A key consideration when 
analyzing the health economic justification for cell-based therapies is therefore the extent to 
which they restore function rather than simply maintain the patient or ameliorate the condition. 
The negation of costs of ongoing patient support, and of managing chronic comorbidities, is 
one of the best arguments to justify the high initial costs of prescribing cell therapies. Most 
importantly, not only detailed cost-effectiveness analyses accounting for the alternative costs 
of long-term palliative care are required for evaluating these novel interventions, but also 
streamlining the manufacturing process and lowering associated costs for developing such 
therapies would be a critical step in achieving a positive cost-benefit ratio. The recently-
suggested considerations to maximize reimbursement potential of cell and gene therapies 
should also be looked at early on in the development process (15). Probably some of these 
therapies, particularly the autologous ones, are not meant for a large scale adoption into the 
medicinal product market. Still, this should not hinder developers, especially academic centers, 
from continuing their research efforts into finding ways to address devastating diseases. In the 
long term, when manufacturing technologies reach a higher level of maturity, most of these 
challenges will be easier to overcome. 
A case study: CMV-specific T cells for adoptive immunotherapy 
We performed a cost estimation of a CMV-specific T cell therapy manufactured in an academic 
GMP facility using the previously indicated costing model (Table 1A-B). To the authors’ 
knowledge, no similar costing data exists in the public domain for such autologous cell therapy 
products. The cost model was employed to calculate the costs of manufacturing the cellular 
product using the recently developed whole protein-spanning overlapping peptide pool-based 
approach with CMVpp65 and IE-1 peptide (29).  With a GMP manufacturing time of 21 days 
for a single CMV-specific peptide stimulated T cell line, we estimated the GMP facility indirect 
costs at €5,670. Direct costs were estimated at €10,390. The final price for a single CMV-
specific T cell line was then calculated to be €16,000.The GMP facility cost of a single T cell 
line was then recalculated with the assumption that another T cell line could be produced in 
parallel, however under strict spatial segregation. In this case, the GMP fixed costs dropped to 
€2,835 for each line. The materials and supplies costs were estimated at €6,190. The remaining 
direct costs (€4,200) were split between the two manufactured cell therapy products. The final 
price for a single CMV-specific T cell product then came to €11,000 (Table 1A-B). Our case 
study thus demonstrates that immunotherapy may offer not only significant clinical advantages 
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to immunocompromised patients, but can also be manufactured at a reasonable cost if an 
appropriate operational model is adopted. Our findings also mirror results from other studies 
examining the need to reduce the economic burden of post-transplantation care (9, 30). 
In summary, commercialization of novel cell therapies, especially autologous products, is not 
a straightforward process; many challenges must be overcome, particularly for academic 
developers to succeed in their mission. The challenge for the sector is surviving financially 
through the lengthy development timelines and overcoming any regulatory hurdles while 
making a successful transition from a production method that has been developed during 
academic research to one that is sustainable in manufacturing to satisfy a potentially global 
market. This needs to be done in the current absence of a consensus view about what operational 
model to adopt and what the incurred costs will be. Therefore, it is today more important than 
ever to generate accurate manufacturing cost estimates that can be useful to eventually 
determine a reasonable price for cellular therapies and achieve the aim of producing a clinical 
benefit in a larger patient population. Only with the application of robust cost and operational 
models will it be possible to create the confidence that must underpin the required investment. 
Academia needs a growing cadre of commercially-aware researchers who are willing and able 
to act collectively at the pre-competitive stages of their work in order to generate the mature, 
tried-and-tested approaches to manufacture at scale that will increase patient access. 
This work was partially supported by a DFG-grant: SFB-TR36, project A2.The authors declare 
no competing financial interests. 
References 
1. Leen, A. M., C. M. Bollard, A. M. Mendizabal, E. J. Shpall, P. Szabolcs, J. H. Antin, N. Kapoor, S.-
Y. Pai, S. D. Rowley, P. Kebriaei, B. R. Dey, B. J. Grilley, A. P. Gee, M. K. Brenner, C. M. Rooney, 
and H. E. Heslop. 2013. Multicenter study of banked third-party virus-specific T cells to treat severe 
viral infections after hematopoietic stem cell transplantation. Blood 121: 5113–23. 
2. Gerdemann, U., U. L. Katari, A. Papadopoulou, J. M. Keirnan, J. A. Craddock, H. Liu, C. A. 
Martinez, A. Kennedy-Nasser, K. S. Leung, S. M. Gottschalk, R. A. Krance, M. K. Brenner, C. M. 
Rooney, H. E. Heslop, and A. M. Leen. 2013. Safety and clinical efficacy of rapidly-generated 
trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic 
hematopoietic stem cell transplant. Mol. Ther. 21: 2113–21. 
3. Gottschalk, S., and C. M. Rooney. 2015. Adoptive T-cell immunotherapy. In Current Topics in 
Microbiology and Immunology vol. 391. 427–454. 
4. Brestrich, G., S. Zwinger, A. Fischer, M. Schmück, A. Röhmhild, M. H. Hammer, A. Kurtz, L. 
Uharek, C. Knosalla, H. Lehmkuhl, H.-D. Volk, and P. Reinke. 2009. Adoptive T-cell therapy of a 
lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. 
Transplant. 9: 1679–84. 
5. Fishman, J. A. 2007. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357: 2601–14. 
9 
 
6. Husain, S., C. E. Pietrangeli, and A. Zeevi. 2009. Delayed onset CMV disease in solid organ 
transplant recipients. Transpl. Immunol. 21: 1–9. 
7. Razonable, R. R., and A. Humar. 2013. Cytomegalovirus in solid organ transplantation. Am. J. 
Transplant 13 Suppl 4: 93–106. 
8. Razonable, R. R. 2011. Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. 
Mayo Clin. Proc. 86: 1009–1026. 
9. Jain, N. A., K. Lu, S. Ito, P. Muranski, C. S. Hourigan, J. Haggerty, P. D. Chokshi, C. Ramos, E. 
Cho, L. Cook, R. Childs, M. Battiwalla, and A. J. Barrett. 2014. The clinical and financial burden of 
pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—
implications for preventative treatment approaches. Cytotherapy 16: 927–933. 
10. Saglio, F., P. J. Hanley, and C. M. Bollard. 2014. The time is now: Moving toward virus-specific T 
cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16: 
149–159. 
11. The European Commission. 2003. Commission Directive 2003/94/EC Laying Down the Principles 
and Guidelines of Good Manufacturing Practice in Respect of Medicinal Products for Human Use and 
Investigational Medicinal Products for Human Use. Off. J Eur Union 13: 22–26. 
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_94/dir_2003_94_en.pdf 
12. EudraLex—EudraLex - Volume 4 Good manufacturing practice (GMP) Guidelines. 2009. 
http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm. 
13. Abou-El-Enein, M., A. Römhild, D. Kaiser, C. Beier, G. Bauer, H.-D. Volk, and P. Reinke. 2013. 
Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel 
tailored model for optimizing performance and estimating costs. Cytotherapy 15: 362–83. 
14. Hourd, P., P. Ginty, A. Chandra, and D. J. Williams. 2014. Manufacturing models permitting roll 
out/scale out of clinically led autologous cell therapies: Regulatory and scientific challenges for 
comparability. Cytotherapy 16: 1033–1047. 
15. Abou-El-Enein, M., G. Bauer, and P. Reinke. 2014. The business case for cell and gene therapies. 
Nat. Biotechnol. 32: 1192–1193. 
16. Octane Technology. http://octaneco.com/octane-download.pdf.  
17. Bajgain, P., R. Mucharla, J. Wilson, D. Welch, U. Anurathapan, B. Liang, X. Lu, K. Ripple, J. M. 
Centanni, C. Hall, D. Hsu, L. a Couture, S. Gupta, A. P. Gee, H. E. Heslop, A. M. Leen, C. M. 
Rooney, and J. F. Vera. 2014. Optimizing the production of suspension cells using the G-Rex “M” 
series. Mol. Ther. Methods Clin. Dev. 1: 14015. 
18. de Wilde, S., L. Veltrop-Duits, M. Hoozemans-Strik, T. Ras, J. Blom-Veenman, H.-J. Guchelaar, 
M. Zandvliet, and P. Meij. 2016. Hurdles in clinical implementation of academic Advanced Therapy 
Medicinal Products: A national evaluation. Cytotherapy doi:10.1016/j.jcyt.2016.02.010. 
19. Cuende, N., C. Boniface, C. Bravery, M. Forte, R. Giordano, M. Hildebrandt, A. Izeta, and M. 
Dominici. 2014. The puzzling situation of hospital exemption for advanced therapy medicinal 
products in Europe and stakeholders’ concerns. Cytotherapy 16: 1597–1600. 
20. Hall, A. K., and M. R. Carlson. 2014. The current status of orphan drug development in Europe 
and the US. Intractable rare Dis. Res. 3: 1–7. 
21. Abou-El-Enein, M., G. Bauer, P. Reinke, M. Renner, and C. K. Schneider. 2014. A roadmap 
toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol. Med. 
20: 632–642. 
22. Blasimme, A., and E. Rial-Sebbag. 2013. Regulation of Cell-Based Therapies in Europe: Current 
Challenges and Emerging Issues. Stem Cells Dev. 22: 14–19. 
23. Maciulaitis, R., L. D’Apote, A. Buchanan, L. Pioppo, and C. K. Schneider. 2012. Clinical 
development of advanced therapy medicinal products in Europe: evidence that regulators must be 
proactive. Mol. Ther. 20: 479–82. 
10 
 
24. Abou-El-Enein, M., and C. K. Schneider. 2016. Deciphering the EU clinical trials regulation. Nat. 
Biotechnol. 34: 231–233. 
25. The European Commission. 2015. Summary of the responses to the targeted stakeholder 
consultation on the development of Guidelines on Good Manufacturing Practice for Advanced 
Therapy Medicinal Products pursuant to Article 5 of Regulation 1394/2007. 
http://ec.europa.eu/health/files/advtherapies/2015_11_pc_gmp_atmp/2015_11_pc_gmp_atmp_summar
y.pdf. 
26. Srivastava, A., C. Mason, E. Wagena, N. Cuende, D. J. Weiss, E. M. Horwitz, and M. Dominici. 
2016. Part 1: Defining unproven cellular therapies. Cytotherapy 18: 117–119. 
27. Abou-El-Enein, M., G. Bauer, and P. Reinke. 2015. Gene therapy: A possible future standard for 
HIV care. Trends Biotechnol. 33: 374–376. 
28. Cruz, C. R., P. J. Hanley, H. Liu, V. Torrano, Y.-F. Lin, J. A. Arce, S. Gottschalk, B. Savoldo, G. 
Dotti, C. U. Louis, A. M. Leen, A. P. Gee, C. M. Rooney, M. K. Brenner, C. M. Bollard, and H. E. 
Heslop. 2010. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year 
experience. Cytotherapy 12: 743–9. 
29. Hammer, M. H., S. Meyer, G. Brestrich, A. Moosmann, F. Kern, L. Tesfa, N. Babel, A. 
Mittenzweig, C. M. Rooney, W. Hammerschmidt, H.-D. Volk, and P. Reinke. 2005. HLA type-
independent generation of antigen-specific T cells for adoptive immunotherapy. Eur. J. Immunol. 35: 
2250–8. 
30. Hiwarkar, P., H. B. Gaspar, K. Gilmour, M. Jagani, R. Chiesa, N. Bennett-Rees, J. Breuer, K. Rao, 
C. Cale, N. Goulden, G. Davies, P. Amrolia, P. Veys, and W. Qasim. 2013. Impact of viral 
reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT 
in paediatric recipients. Bone Marrow Transplant. 48: 803–808. 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
 
Table 1: The variable costs of manufacturing GMP-grade CMV-specific T cell products. The variable 
resources of the manufacturing process were identified according to the cost model. 
 
 Unit fixed costs 
(€) 
Unit variable cost 
(€) 
Total unit cost 
(€) 
CMV-specific CTL (1 line/lab) 5,670 (35%) 10,390 (65%) 16,060 
CMV-specific CTL (2 
lines/lab) 
2,835 (25%) 8,290 (75%) 11,125 
 
Table 1-B: The fixed and variable cost shares in the manufacturing of a single CMV-specific T cell 
product. The fixed costs represent 35% while the variable costs represent 65% of the total manufacturing costs. 
If 2 CMV- specific T cell products are produced in the same GMP laboratory, the fixed costs represent 25% of 
the total manufacturing costs.   
 
 
 
 
 
 
 
Variable Resources  Description Variable costs (€) 
Materials and 
supplies 
Media and supplements & Plasticware 5,660 
Reagents for the CliniMacs 
- PepMix HCMVA (pp65) 
- PepMix HCMVA (IE-1) 
420 
Garments  110 (10 sets) 
Personnel Production personnel 2,200 
Utilities  
Maintenance 
Electricity, water & medical grade gases  350 
Corrective maintenance 
Quality 
Management 
system 
-Depreciation of media-fill,  process 
validation and fees for manufacturing 
authorization 
1,650 
-Cleaning and environmental monitoring 
Batch Release Testing (testing for sterility, 
mycoplasma, endotoxin and other items 
required by the guidelines) 
Total   10,390 
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Figure 1: A hypothetical break-even analysis of manufacturing GMP-grade cell therapy products. The figure 
presents a cost-volume-profit graph for GMP grade cell lines. Notice that when no cells are produced, fixed costs 
are X1 €, resulting in a loss of 100% of these costs per year. As manufacturing volume increases, the loss decreases 
by the contribution margin for each cell line produced. The cost and revenue lines intersect at the break-even point, 
which means zero loss and zero profit (fixed and variable costs are covered). Then, as manufacturing increase 
beyond this break-even point, we see an increase in income. The unit contribution of fixed costs decreases by half 
(X4 €) when the production volume reaches Y2. This point can be reached, for instance, by producing two parallel 
cell lines in one GMP laboratory using strict spatial separation. 
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